Updated:
Guangzhou-Israel Biotechnology Fund
Guangzhou Biotechnology Investment Fund (GIBF) promotes life sciences technologies in China through cross-border investments and international collaborations.
Guangzhou-Israel Biotechnology Fund
Guangzhou Biotechnology Investment Fund (GIBF) promotes life sciences technologies in China through cross-border investments and international collaborations. It creates added value for overseas companies looking to expand in China and partners with selected overseas companies to establish new JVs in the Chinese market, enabling the foreign companies to control and manage their new subsidiaries as the majority shareholders. GIBF focuses on innovation in the Biotech and MedTech fields and provides resources for clinical trials, NMPA submissions, commercialization and manufacturing in China.
General information
Firm type
Venture Capital
Year founded
2016
Location
Region
Asia
Country
China
City
Guangzhou
Corporate office
Guangzhou, China
Principals
DR. YEHOSHUA(SHUKI) GLEITMAN - Founding Partner and Chairman
PROF. SHLOMO NOY - Founding Partner and Chief Medical Officer
AVNER LUSHI - Founding Partner and CEO
CARL GENG - Founding Partner and General Manager
Sector focus
Frequently asked questions
What investment stages does the Guangzhou-Israel Biotechnology Fund target?
The fund targets early-stage investments, spanning seed, start-up, and growth stages within biotechnology, medical devices, and digital health. This stage flexibility accommodates both nascent IP transfer opportunities and more mature Israeli firms seeking Chinese commercialization partnerships.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: